On October 19, 2022 Hemispherian AS ("Hemispherian” or the "Company"), a Norwegian preclinical pharmaceutical company focused on small molecule cancer therapeutics targeting the DNA damage response, reported a successful European Innovation Council (EIC) Accelerator grant application (Press release, Hemispherian, OCT 19, 2022, View Source [SID1234622173]). This grant will provide EUR 2.5M in grant funding and the jury recommends an additional EUR 7.5M in equity financing from the EIC fund. Financing from the EIC accelerator will be used to advance GLIX1, one of Hemispherian’s lead assets, through a phase I and phase II clinical trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to accept funding through the EIC accelerator program. This funding will ensure the successful development of Hemispherian’s lead asset, GLIX1, through phase I and phase II clinical trials."
— Adam Robertson, PhD, Chief Scientific Officer, Hemispherian